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Abstract 
The role of innovation in business has long been recognized, but increased competition 
among companies has forced them to seek new strategies. In this paper, two types of 
strategies will be compared. In the first type, patents play a key role in protecting 
businesses from the entry of new competitors (block). The second strategy is 
characterized by repeated introduction of new products on the market (run). The focus 
of this article will be on the implications of these strategies for the firm and its internal 
procedures. Specifically, we investigate how the choice of innovative strategy 
determines the type of project management and knowledge management that the 
company adopts. 
Based on a case from the chemical and pharmaceutical industry, we will demonstrate 
that both types of strategy involve “heavyweight project management.” In the block 
strategy, learning processes are mainly dedicated to scientific knowledge rather than 
market knowledge. Consequently, development partnerships are established primarily 
with academic units and research centers of other companies. In contrast, in the run 
strategy, repeated interactions with customers occur during the development process. 
This “learn and probe” process is aimed at iteratively defining the new product with the 
customers. Development partnerships involve the clients themselves and enable joint 
learning.  
Because very successful companies have recently combined these two types of 
strategies, we will elaborate on the implications of such a dual strategy for the 
company. As each strategy alone is associated with a specific knowledge management 
approach, internal conflicts might emerge when they are combined. We will conclude 
with organizational procedures that might reduce such conflicts. 
Résumé 
L’importance de l’innovation dans la concurrence entre firmes, depuis longtemps 
soulignée, n’a fait que s’accroître ces dernières années. Les firmes ont été amenées à 
développer des stratégies d’innovation de plus en plus variées. Nous caractérisons deux 
stratégies typiques qui peuvent également être combinées. La première est une stratégie 
de blocage des concurrents par l’innovation ; la seconde est une stratégie de course à 
l’innovation. Le texte s’intéresse aux conséquences de ces deux stratégies sur 
l’organisation interne de l’entreprise. Quel type de management de projet et de 
management des connaissances impliquent-elles ? L’analyse est développée à partir du 
cas d’une grande entreprise chimique et pharmaceutique.  
Nous  discutons également les implications d’une stratégie double, associant 
protections par brevets et course à l’innovation produit. Compte tenu des conflits 
internes associés à une telle combinaison quelles solutions organisationnelles seraient 
de nature à les réduire ?   
 In recent years, innovation has become increasingly important in defining business 
strategies. Although innovation has always been a factor in the growth and 
competitiveness of a company, various innovative strategies have emerged in response 
to the rapid changes in the economic environment. 
Traditionally, innovative products dominated the market for long periods of time. In the 
chemical and pharmaceutical industry, for example, aspirin, an analgesic drug, 
dominated the market for decades without the threat of any similar product. Such was 
also the case for nylon and other types of polyester. For these innovations, patents 
guaranteed that the company would not be imitated for a certain period of time and 
would get to keep the benefits of the investment for itself. Generally, patents serve as 
an incentive for companies to develop new scientific knowledge, new products and 
processes.  
Although patents build strong barriers against new entrants, business history has 
repeatedly shown that the technical advance of a company is temporary. First of all, 
new competitors take the opportunity of technical breakthroughs to take a dominant 
position. Such has been the case, for example, in the photographic industry with the 
evolution from chemical film to digital format. Then, other competitors develop generic 
products when patents have expired taking a large portion of the market share because 
of cost advantage. In the pharmaceutical industry, government agencies encourage such 
a strategy in order to lower the price of drugs for which patents have come to an end. In 
the food industry, generic products have also developed as a result of the growing 
power of discount department stores. 
The period during which a company can count on a competitive advantage related to an 
innovative product has increasingly become shorter. Consequently, companies have 
sought innovative strategies to extend their competitive advantage over a longer period 
of time. One innovative strategy consists of repeatedly introducing new products. At 
such a high pace, the company reestablishes its competitive advantage recurrently. This 
race to innovation race also provides a solution to the decrease in demand that results 
from the saturation of markets once diversified and renewed products are offered. But 
companies adopting such a strategy need to shorten their development cycle and reduce 
their costs. As new product life cycle become shorter, development costs have to be 
reimbursed over a shorter period and over smaller sales. Development lengths are 
generally directly related to their cost.  
A second innovative strategy focuses on reinforcing barriers to entry in order to contain 
competition. The protection of the core innovation is reestablished by adding 
complementary innovations, either in the process or with related products, which can be 
patented. Not surprisingly, the propensity of firms to patent has increased. 
Although these two strategies⎯one consisting of running from one new product to the 
next (run) and the other of blocking new entrants (block)⎯stand in opposition to each 
other, firms increasingly tend to combine them. For example, companies in the 
specialty chemicals industry introduce new products at a high pace and have a high 
propensity to patent. The phenomenon is similar in the computer industry, where 
products quickly become obsolete and intellectual property is carefully studied. This 
trend also exists in less technological sectors such as cosmetics (L’Oreal) or appliances 
(Tefal). 
The purpose of this article is to analyze the implications of each of these strategies 
(block and run) for the internal organization of the firm. What kind of organizational 
processes actually support the repeated introduction of innovations on the market? Are 
they similar to the processes that enable the company to develop innovations protected 
by long-term patents? To be sure, project management and project portfolio 
management arelikely to be key issues in the run strategy. Short development time is 
required to repeatedly introduce new products. In contrast, project management appears 
secondary for the block strategy where filing for patents is the key issue. Management 
of highly skilled workers and the organization of research centers are the main concern. 
Does the empirical analysis of companies exemplifying one of these strategies confirm 
these trends? How do firms manage to combine these two strategies if their internal 
consequences profoundly differ? 
We will first elaborate on the implications of these strategies on internal processes of 
project management and experts management that we might expect based on the 
literature. Then the case of a large chemical and pharmaceutical company will be 
analyzed. The chemical branch of the company will enable us to discuss the implication 
of the run strategy on the internal organization. This branch commercializes diversified 
specialty chemical products frequently renewed in order to cope with customer needs 
and competition. In contrast, the pharmaceutical branch exemplifies the block strategy. 
After having discussed these two strategies separately, we will investigate how a 
company might combine them. What are the organizational conditions associated to a 
dual strategy? What tensions are likely to be encountered? 
 
I – Organizational processes and innovation strategies in the literature 
According to the literature, the organizational processes associated with innovative 
strategies are the project management methods and the knowledge management 
routines (Ben Mahmoud Jouini & Midler, 1998, Weil 1999, Robinson & Chang 2002).  
Project management 
Over the past twenty years, new product development has been widely analysed. One 
project management model⎯the “heavyweight project management” model⎯stands as 
a synthesis of numerous works on this subject. Its efficiency, as measured by 
development lead time, has been demonstrated in a variety of industries. Consequently, 
most firms have tried to implement this project mangement model ever since. 
Based on the research of K. Clark & T. Fujimoto (1991), M. Cusumano & K. Nobeoka 
(1992) and C. Midler (1993), project management methods are characterized along the 
following dimensions: the project manager position (1), multi-expertise teams (2), 
overlapping phases and concurrent engineering (3), “learn and probe” process (4) and 
development partnerships (5). 
Project manager position. In the “heavyweight” project management model, projects 
are coordinated by a project manager who has enough status in the company to affect 
the basic direction of the project (i.e., to revise the target and switch outside partners). 
The project manager also works the project full-time and without interruption until it is 
completed.  
Multi-expertise teams. The geographical proximity of the individuals involved in the 
project, at best collocated on project floors, is a first attribute of a multi-expertise team. 
Regular, frequent, and open-ended meetings which focus on choosing options and 
drafting working plans and are not just dedicated to reporting is a second. Third, these 
project teams bring together different functional specialties. To assess the 
multifuntional character of the team, the typical functions of the firm are considered 
(R&D, engineering, production, and marketing). These typical functions in the industry 
studied translate into: product development, process development, customer approval of 
the product and start-up of production installations. 
Concurrent engineering. This characteristic of project management is assessed 
according to the overlaps in typical project phases: concept definition, preliminary 
study, detailed product and process design and production trials. Here again, the major 
phases are adapted to the industry studied. 
Project management will be deemed “heavyweight” when it has these three 
characteristics: high status of the project manager, multi-expertise team and concurent 
engineering.  
Learn and probe process. The involvement of selected customers in iteratively testing 
new products has been related to successful innovation by several authors (Ackrich, 
Callon & Latour 1988, Iansiti & Clark 1994, Lynn, Moronne and Paulson 1996, Tabrizi 
and Eisenhardt 1995). It has been studied most specifically in the case of breakthrough 
innovation. But understanding what customers see as a source of value is critical even if 
innovation is more incremental, as it is often the case in the run strategy. The customer 
relationships will be analysed in focusing on the role the customers have in testing 
product prototypes or first versions during the development process. 
Development partnerships. Since the design of new products involves not only one 
company but also other organizations, the network of organizations in which the 
innovation process takes place is a key concern. The type of relationship established 
with other players in the network has an impact on the performance of the innovation 
process. Partnerships with suppliers responsible for the development of subassembly 
during the design process relates to improved efficiency, as shown in studies in the auto 
industry.  The players involved in development partnerships (customers, suppliers, 
university research centres, competitors, distribution industry etc.) will be listed to 
characterize the project management on this dimension. 
Knowledge management. 
In addition to work emphasizing the role of project management in the efficiency of 
new product development, research studies have recently stressed the importance of the 
learning processes that take place between experts and within project teams and, more 
broadly, knowledge management routines. The development of the new competencies 
that will be needed because of the evolution of technologies is a primary issue (Teece 
1998, McEvily & Chakravarthy 2002). Recording and maintaining  know-how which 
have contributed to past technological success are also important. Tacit, situated and 
embodied knowledge forms the main body of organizational knowledge that raises the 
issue of how to identify, share and memorize this knowledge in the firm. Knowledge 
management routines will be analyzed in differenciating two levels.  
Individual incentives. The incentives for individuals to develop new knowledge is the 
first focus. Following with the studies of Cockburn & Henderson (1998), existing 
corporate measures to promote scientific production and foster professional networks 
(communication at symposia, the publication of articles, patents) will be identified. This 
emphasis on the individual level  is consistent with Mintzberg’s professional 
bureaucratie model, in which competencies are held by individual professionals. 
Collective learning processes. The organizational devices designed to promote learning 
among groups are also critical to knowlege development. Following Allen’s work on 
interpersonal communication and Nonaka (1994) and Weil (2000) results, formal 
methods for sharing the competencies gained by one expert in the course of working on 
a project with a group of experts (workshops, newsletters, clubs) or for building new 
knowledge on a team base will be analysed. 
Which project management method and knowledge management routines better fit with 
each of the strategies oulined at the beginning of the article? Based on our literature 
review, what might we predict? 
Based on Afuah’s definitions (1998), block strategy will be used to refer to the 
innovative strategy of a firm that attempts to erect barriers to entry in order to protect 
the market position taken by an innovation. For example, some firms create barriers by 
focusing on hard-to-imitate competencies and assets, while others establish intellectual 
property rights.  
In contrast, in the run strategy, the company would regularly modify specific 
components of its products or their integration so as to offer customers additional value. 
The rationale of such a strategy would be that barriers to entry associated with an 
innovation are temporary and can be circumvented. Thus, sustainable profitability relies 
on the continuous and rapid renewal of products (Benghozi, Charue-Duboc & Midler 
2000, Weil & Hatchuel 1999). This process of repeated innovation reccurently gives the 
company an edge over the competition. The company needs to be able to rapidly 
develop new products. The company also needs to possess market knowledge: who are 
the customers, how do they use the products, what properties are the most valuable? 
Implementing this strategy requires internal organizational capabilities that will be 
stated as hypotheses. The hypotheses are based on the literature and tested with the case 
in the chemical and pharmaceutical industry.  
The first hypothesis relates the run strategy to the heavyweight project management 
model (H1). Several works have shown a correlation between this project management 
model and a reduction of the development cycle time which is a key factor in the 
efficiency of this strategy. Second, a “learn and probe” process is expected to be part of 
the project management (H2). Though this concept has been developed for radical 
innovation, this iterative process, allowing many interactions with future customers 
while the new product is elaborated, shall be adopted in firms having a run strategy. 
The run strategy relies on the ability of the firm to cope rapidly with the evolution of 
the market. “Learn and probe” processes enable the project teams to adapt the product 
to customer needs and enhance market knowledge. Our third hypothesis relates to 
knowledge management. The run strategy should be associated with a focus on 
collective learning processes and organizational artifacts dedicated to fostering them 
should be implemented (H3). As stated earlier, run strategies are adopted based on the 
assumption that a competitive advantage relating to an innovation is only temporary 
that products get quickly imitated that patents will be circumvented. Such is often the 
case when technical and scientific knowledge mobilized is mature. Completing the 
development of a new product then implies that the project team to address and 
overcome specific issues. Collective learning processes more than sharp expert’s 
knowledge are critical for such problem solving (Nonaka 1994). 
As for the run strategy, the block strategy rests on organizational capabilities that will 
be emphasized. The differentiating characteristics of the product, its usage, its cost, or 
its production process determine the profitability of the innovation for the firm. The 
profit is generated by the innovation as long as no other company manufactures and 
commercializes a similar product at the same price. The possibility of patenting and the 
difficulty in imitating or in overturning the patent are the key factors that ensure the 
durability of profit (Teece 1986). Thus, the issue is not so much the introduction of a 
new product on the market but the filing for a patent and the primacy. The heavyweight 
project management model would not be appropriate in this situation. Concurrent 
engineering may even slow down the patenting process as the work necessary to file for 
a patent takes place during the early phases. In contrast, a sequential pattern of 
development may allow focusing on early development phases. As a result, filing for a 
patent might be accelerated. The secrecy on important findings might also be more 
easily protected this way. Thus, the block strategy should not be related to heavyweight 
project management (H4).  
In addition, this strategy is more likely to be adopted in industry relying on scientific 
disciplines experiencing a rapid development. In such a context, relationships with 
academic units are critical to rapidly absorb and take advantage of the latest 
developments and establish intellectual property rights. Development partnerships with 
academic units are expected (H5). The discovery phases of projects are crucial because 
they establish the basis of any patent application. Scientific expertise and the 
elaboration of new knowledge on the product determines the efficiency of these phases. 
The experts of the company, specialized, highly skilled and recognized in the scientific 
community, are the one whose input is critical. Thus, managing human resources, 
especially experts⎯enhancing their creativity and supporting them in developing 
professional networks⎯are the priority. Knowledge management will emphasize 
individual learning processes (H6). The incentives to publish and patent will thefore be 
dedicated to these experts. 
 
dimensions Run strategy Block strategy 
Project mgt 
     heavyweight 
H1 + H4 - 
     Learn and probe H2 + No prevision 
     Dvt partnerships No prevision H5 + 
Knowledge mgt 
      Individual incentives 
 
H3 bis - 
 
H6 + 
      Collective processes H3 + H6 bis - 
 
+ stands for a positive relationship ; --  stands for a negative relationship 
 II – Method 
We will consider the case of a major french chemical group which has been undergoing 
a strategic reorientation and a thouroughgoing review of its project management 
procedures since 1992.  
The pharmaceutical branch provides a typical example of block strategies; indeed, 
patents play an extremely important role in the drug industry, not only in protecting 
revenues while development costs are very high but also in securing marketing 
authorizations. The newness of active ingredients and of their therapeutic effects is 
often a prerequisite. This provides a way for regulatory agencies to orient firms’ 
strategies. 
The chemical branch, which has shifted its focus to specialty products, is typical of the 
run strategy. Indeed, although innovations generate applications for patents, new 
products are also being introduced at a fast pace. In the chemical industry, often 
different products may have similar use property and the patent is only on the specific 
prodcut developed it doesn’t block new entrants with a slightly different product. The 
sales of products that have been on the market for less than three years show this 
strategy of repeated innovation.  
This company is also an interesting case because its chemical and pharmaceutical 
branches were once merged. The businesses gradually became differentiated as the 
organization grew and created divisions. Finally, after a period of steady 
decentralization, there was a total split of the two businesses, which were spun off into 
two independent companies. This past allows us to link similarities and differences to 
the specific nature of the businesses and to the strategies implemented in the companies. 
Our study was carried out with C. Midler and first focused on changes in project 
management which were going on within the group, particularly with respect to 
activities in the Chemicals and Health divisions. The material was compiled by one of 
three methods: a training program for project managers (access to some one hundred 
on-going projects within the company); a more in-depth analysis of some fifteen 
projects based on interviews with project teams; and, finally, a longitudinal approach 
following a project from inception through to its conclusion (2 years). In a second 
phase, the study was focused on the evolution of the organization of research 
departments in relation with competencies development: the reorganization of a 
research centre in the pharmaceutical branch going along with reorganization of the 
whole R & D department ; the historical process of development of key competencies 
that enabled the development of innovation in a specific line of business of the chemical 
branch. 
We begin in analyzing and characterizing the pharmaceutical branch, the project 
management and the knowledge management processes. The chemical business and its 
methods of organizing development processes is then introduced. After having 
reviewed the main differences in internal organizational processes related two these 
different strrategies, the main issues an organization may face in trying to combine 
them is discussed. 
 
III — The pharmaceutical branch: a prime example of a block strategy 
What is an innovation project in this field ? Pharmaceutical innovation projects identify, 
develop and market new medications.  
The regulatory agency that authorizes the marketing of medications requires projects to 
be organized into major phases, labelled : discovery, I, II and III. The discovery phase 
is restricted to animal testing. But many parameters have to be established already at 
this stage (the product injected, the final steps in the manufacturing processes) in order 
to get the authorization for human testing, the main objective of this phase. Phases I to 
III involve clinical trials in humans, only dosages and administration protocols may be 
revised during phase I. 
The starting points of projects are the pathologies for which researchers are attempting 
to devise therapies and ways of acting on an illness which constitutes concepts. A 
concept is first expressed by a type of molecule and a hypothesis concerning its action 
on the illness. Specifying the concept in detail and designing tools for it leads 
researchers to draft a protocol that describes the molecule and the sought-after property, 
a production method, a method for verifying the efficacy hypothesis using an animal 
model and an explanation of the predictability of the animal test in humans.  
III – 1 – Project management processes 
Now that we have rapidly described the main steps of the development of an innovation 
in the pharmaceutical sector we shall characterize its project and knowledge 
management processes. Our analysis of the pharmaceutical business looks more 
specifically at the functioning of its vaccine research department.  
Projects are structured to develop innovation as early as in the initial discovery phase. 
Right from the start, a mini-team is created that included experts in all the areas 
required to successfully complete the project (identification of the active ingredient, 
development of the manufacturing process, strategy for validating efficacy and non-
toxicity). Until a recent reorganization, the project manager was the department’s 
manager. But the departments were organized around therapeutic targets resulting in an 
almost perfect overlap between department scope and project scope. The department’s 
manager combined scientific expertise in one discipline and in the therapeutic target, 
supervisory authority over team members and the status associated with his 
management responsibility—served as the project manager. He provided project 
monitoring and continuity. The change of organization of the research center led to a 
classic matrix structure , splitting up its hybrid research/project departments. To 
strengthen projects, the project manager was assigned to a more senior level in the 
hierarchy (reporting directly to the R&D manager of the branch) and involved also in 
the clinical development stage.  
Contrary to our hypothesis set in part I, even in a sector such as the pharmaceutical 
industry, where scientific expertise and patents are key to the success of innovation, 
companies implement a heavyweight project management model. We qualify of 
“heavyweight” the project managers because of the power they had to steer the 
exploratory phase toward one or another type of active ingredient or efficacy 
hypothesis, to determine budget uses and to ask for budget revisions from his reporting 
units. The project teams include various competencies in product development, testing 
(efficacy, toxicity), process development and the preparation of approval requests.   
The third characteristic chosen to specify project management methods is concurrent 
engineering, or “overlapping phases”. There was no line drawn between a highly 
exploratory research activity, during which creativity would be protected and fostered, 
and a later, separate phase in which development work would be well-defined and 
equipped with tools. However, a relatively sequential schedule was imposed by the 
approval authority. Researchers are not allowed to conduct efficacy tests in humans 
before all the non-toxicity tests are complete. In the same way, the production process 
must be established before efficacy tests can begin.  
In the pharmaceutical field, the pharmaceutical group, health authority and physician 
agree on a method for certifying product efficacy. The decisive part of the probing 
process takes place during the discovery phase. An efficacy test featuring a model of 
the illness (selected strain of the virus, bacteria or diseased cells, for example) and a 
behavioural model of the human body (animal model, test on a particular type of cell) 
serves as the primary and only way to undertake the learn and probe process. Then tests 
are conducted on a stastically representative sample of human being  but it is already 
for the purpose of validation of the efficacy of the compound and not typically learn 
and probe process. As a matter of fact it is very difficult to adjust iteratively the 
medication. For ethical reason, it should be optimized before administration to human 
being. Whether the client is the patient, the prescribing physician or the public health-
care agency that will authorize the medication and negotiate the level of reimbursement, 
there is no direct association with the design process. 
Pharmaceutical “inventions” are often the work of a network of people. One has only to 
think of diseases such as AIDS or cancer to understand how impossible it is to rely on a 
single player to identify a new medication or vaccine. On the opposite, they are the by-
product of a combination of more in-depth understanding of the illness, the 
identification of a bacterial or viral strain that causes an illness in laboratory animals 
similar to the one in man and the discovery of a simple test that makes it possible to 
show the efficacy of a substance on a cellular process disrupted by disease. Advances 
on several different scientific fronts combine to show, at a given point in time, that a 
molecule has a specific  efficacy in a test and overall efficacy on an illness or certain 
consequences thereof. Thus the current trend is a move toward forming various types of 
partnership: partnerships with university laboratories to explore basic topics 
unconnected with projects, but which cement the tie in the network; partnerships to 
pursue a specific topic, in which the university laboratory has special expertise; genome 
sequencing contracts; a partnership between pharmaceutical companies with two 
different approaches to the same illness; and so on. Most of these relationships are 
being developed in conjunction with carefully studied intellectual property strategies.  
 
Characteristics Block strategy exemplified by 
the pharmaceuticals branch 
hypo 
Project management methods   
Heavyweight project manager 
Multi-expertise team 
concurrent engineering 
 
Yes 
 
H4 
No 
Learn and probe process No  
Development partnerships Yes 
(with academic research center and 
pharmaceutical company) upstream 
partnership 
H5 
yes 
Knowledge management routines   
Individual incentive  Limited H6 
yes 
Collective learning processes Yes  
No 
III – 2 –Knowledge management routines 
The first knowledge management routine outlined in our literature review consists of 
formal, specific incentives tying individual compensation to the number of 
communications, publications and patents produced. In the case studied, there was no 
formal or systematic definition of individual goals or bonus specifically associated with 
a patent application. Involvement in outside scientific networks was informally (and 
positively) taken into account in individual researcher evaluations.  
The main change we saw was the decision to introduce inter-project working group to 
promote cross-project learning. It occured when the research centre shifted to a matrix 
organization. Both evolutions strengthened the research centre’s emphasis on 
competency and grouped various experts with the same competency who were assigned 
to different projects. 
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Two types of formal processes were introduced. One was dedicated to the 
homogeneisation and optimization of methodologies developed while working on 
various projects. The other was “technological or exploratory projects”. They were 
aimed at the development of a new technology or the exploration of a phenomenon not projet
well undersood identified in several projects. Formal process inspired by project 
management techniques were used: goals sheet, schedule, intermediate deadlines, 
budget, manager and team involved.  
The important thing to stress about this cross-project team groups is that the collective 
nature of learning processes and competencies in an organization is taken into account. 
The emphasis is not placed only experts management but also on collective learning 
processes and settings, which have to be managed, focused, monitored...  
The topics of the technological projects were also discussed collectively. The 
department head enjoys a great deal of room for initiative. But discussion with 
department experts, the other specialists and the project heads seemed important in 
choosing topics actually explored and support topics. 
We could observe knowledge management mechanism both at individual level and at a 
collective level. Our hypothesis concerning knowledge managment is then partially 
validated because even in a very knowledge intensive sector such as drug discovery, the 
stress on collective learning seems important in research centers. 
 
IV – The chemical branch: the turn toward a run strategy  
 The analysis of innovation in the pharmaceutical branch led us to characterize the 
implications on project management and knowledge management of a “block” strategy. 
What are these implications in the case of a business adopting a run strategy ? 
In the chemical branch, innovation projects involve devising new chemical compounds 
with properties that are of particular interest regarding their applications. For instance, 
researchers may develop a new mastic silicone that enables workers to clean tools using 
water instead of a solvent, a new silica that adds resistance properties to tires while 
solving the tire recycling problems, a new, lead-free coloured pigment. Most involve 
well-known and identified families of molecules. However, one property of the family 
is reworked and optimized to tailor it for specific uses either by means of the molecule 
chosen, the way it is formed, the formula or some other method. Innovation consists of 
devising a more or less new chemical compound, produced using a more or less new 
process, and featuring an application property that past materials did not offer or 
offered in inferior form. 
IV – 1 – Project management  
During the study, the role of the project manager was strengthened. Now, overall 
project managers are responsible for exploring specific application properties that might 
be improved as well as the potential of technical avenues under consideration: these two 
processes take place concurrently. Project managers are dedicated to the project and 
responsible for the profit generated by the new product. They coordinate 
“upstream marketing” players, who concentrate on understanding the market and 
competing products as well as the properties that could differentiate potential 
innovations within the product line being studied. They also coordinate research 
personnel involved in developing the product and the process used to characterize it. 
They thus qualify as “heavyweight” project managers, even though their status within 
the company is not equivalent to that of a project director in the auto industry. Indeed, 
project managers are responsible for the project as a whole and not just a piece of it or 
the contribution of a particular occupation: they enjoy some leeway in targeting the 
project (market position, technical choices), and they oversee a project team with 
multiple competencies—product research, process research, marketing and 
industrialization. 
The formal procedures for innovation projects was drafted and listed several phases. 
The firm devised the tools in order to spell out the prerequisites for moving from one 
phase into another; examples include tests that must be completed before committing to 
the heavier investment of financing pilot or industrial facilities. In practice, project 
managers used this standard project development plan as a reference for deciding when 
to carry out work concurrently, if it was needed given the specific requirements of the 
project and the deadlines, and to evaluate the risk of this overlapping. 
The firm has stepped up the number of its partnerships with manufacturing customers. 
Its goal is to work out the desired application properties and the tests for measuring 
those properties with them in order to optimize the products under development. These 
relationships differ from traditional contracts to purchase raw materials in that they 
begin when the product is still in the development stage. The advantage for the 
customer is that it can guide the innovation process of its supplier, so as to end up with 
a compound especially well suited to its needs. The risk, however, is that the 
development process will not be successful. To combine competition among suppliers 
for the customer and access to more than one customer for the supplier, the profit-
sharing formula incorporated into these partnerships consists of an exclusive, short-term 
contract for, say, one year. This again highlights the context of repeated innovations—
to give a competitive advantage to a player, even if only for one year, is motivation 
enough to sign a certain number of partnership deals.  
Partnerships with customers enabled a learn-and-probe-type iterative process. The 
second level at which learn and probe again became important is at the level of strategy 
itself. The repeated introduction of new products lead to a view in chemicals similar to 
the one existing in the software industry, i.e. in terms of successive generations. The 
company introduce a chemical compound knowing that the product still has a few 
“bugs”, but also offers qualities that set it apart from the competition and could help the 
first generation achieve significant market penetration. Its weaknesses will be improved 
during the development of a second generation. 
As hypothesized, the heavyweight project management has been developed in the 
chemical branch to undertake the run strategy with its turn towards specialties. Both 
partnerships and learn and probe processes have been set up with customers in order to 
elaborate new products in response to to new or more focused needs as soon as 
identified. 
IV – 2 – Knowledge management routines 
Knowledge management studies often skip over the question of the nature of the 
competencies and knowledge to be developed or maintained and updated. In contrast, 
strategic studies discuss core competencies but do not delve into the organizational 
processes that support their development. Attempts to answer this question are 
inevitably highly controversial. However, using this kind of interpretive grid in an 
industrial case assumes that one can at least specify which competencies the firm 
considered worth developing to promote innovation before focusing on the procedures 
introduced. Given the nature of chemical innovation projects, the key competencies 
identified were :  
-skills in developing tools to measure the desired usage properties,  
-competencies in relating the physicochemical parameters of compounds to the 
application properties  
-skills in relating the functional parameters of a process to the physicochemical 
parameters of the compound.  
The first step was to design structures: to add application laboratories to the 
organizational chart, to form applicability teams and to define “development and 
innovation manager” functions. The departments were created based on the 
development of specific skills related to the firm’s needs and not on existing 
competencies outside the company. This department could borrow on various existing 
theoretical databases from the disciplines to go on on specific types of problem  
Thus, the application laboratories did not just evaluate or describe products: they 
developed tests able to assess usage properties quickly using small samples, and also 
gained an understanding of the mechanisms that conferred the usage properties, starting 
by linking physicochemical characteristics to the usage properties. 
Although the strategic shift to specialty chemicals prompted a restructuring of research 
departments and a redefinition of expertise fields, there was no significant change in the 
management of individuals. There was no formal incentive tying the number of patents, 
publications and so on to bonuses. This type of incentive to encourage researchers to 
become involved in academic networks was not singled out as a priority, yet patents 
and intellectual property were a vital aspect notably in the partnerships with 
manufacturing customers.  
Cross-project sharing of specific competencies acquired through different projectswas 
not organized per se. Scientific and technical mentors or senior experts were assigned to 
act as coaches to junior researchers and serve as a competencies resource. They were 
therefore in a good position to know about the specific problems and development work 
being done on different projects and to take part to cross-fertilization. However, 
projects were much shorter-lived in chemicals. As a result, the succession of projects 
and the assignment of staff to different projects also helped inter-project knowledge 
acquisition. 
Finally, technology projects were set up to explore themes involving different products 
or processes. A three-year programme was usually drawn up, and a team combining 
relevant specialists, sometimes drafted across departmental lines, was established. 
 
Characteristics Run strategy exemplified by 
the specialty chemicals branch 
hypo 
Project management methods   
   Heavyweight project manager 
   Multi-expertise team 
   Concurrent engineering 
 
Yes 
 
H1 
yes 
   Learn and probe process Yes H2, 
yes 
   Development partnerships Yes  
(with customers) 
 
Knowledge management routines   
   Individual incentive  No H3 
no 
   Collective learning processes No-  
positions of senior experts, 
successive generations of new 
products building on the 
competencies developed in past 
projects   
H3 
yes 
 
V-Discussion 
Our results are of three types: (1) wether the hypotheses were validated by our 
empirical analysis; (2) statements that can be drawn from our empirical analysis but 
about which no hypothesis could be developed from the literature; (3) the main 
differences in the internal organization of businesses adopting these two opposing 
strategies. Finally, we discuss the difficulties of adopting a “combined” strategy and 
specify the conditions that might reduce the conflict. 
Hypotheses H1 and H2, about the run strategy, predicting the adoption of a 
heavyweight project management and “learn and probe” processes, are confirmed. The 
parallel hypotheses (H4, H5) for the block strategy are only partially confirmed. 
Development partnerships with the academic units were associated with the block 
strategy as expected. Contrary to our prediction, the block strategy evoked a project 
management style very similar to the heavyweight project management model. 
 The hypotheses concerning the knowledge management processes are not confirmed. 
In the run strategy, no organizational device specifically designed to enhance learning 
processes either at an individual level or at a collective level was implemented. In 
contrast, in the block strategy, knowledge management routines were observed at both 
the individual and collective level. The collective level even appeared to be the main 
focus of the line management at the time of the study. Different workshops were set up 
to facilitate knowledge exchanges between experts as well as between the technicians. 
In the run strategy, product development processes are short. As a consequence, experts 
assigned to a project quickly reinvest their knowledge on other projects and share it 
with other project team members. This pace and the regular recomposition of project 
team facilitate the exchange of knowledge. In contrast, in the pharmaceutical industry, 
development processes take often more than 8 years, teams are rather stable and 
dedicated to a project for several years. As a consequence, routines specifically aimed 
at facilitating collective learning were set up. 
Two organizational consequences of the run strategy appeared to be very important in 
the case studied and were not adressed in the literature. The first consequence is the 
development of partnerships with customers. As predicted in our hypothesis, “learn and 
probe” processes were structured with customers during the development phase. In 
addition to this frequent contact with selected customers, development partnerships 
with customers were set up in order to develop generic knowledge linking some 
properties the customers were interested in with the intrinsec physical or chemical 
characteristics of the products. Development partnerships have been outlined in the 
litterature, but those analyzed were initiated by big companies to deal with their 
suppliers.  Here, development partnerships with customers are a strong characteristic of 
a business with a run strategy. 
A second element appeared important and relates to the knowledge management 
strategy of a business having a run strategy. As mentioned earlier, no specific 
organizational artifact dedicated to enhancing learning processes either at an individual 
level or at a collective one was identified. There was an emphasis on how departments 
were structured within the research function. Depending on the kind of expertise housed 
in a particular department, the knowledge shared between experts and the topics on 
which new knowledge was built varied. In the pharmaceuetical branch, experts having 
the same academic background and developing the same academic specialty were 
grouped even if they were working on very different molecules and therapies for very 
different diseases. The aim of such a grouping was to enhance the shared knowledge in 
relation to the evolution of the academic discipline. In contrast, in the chemical branch 
of the firm, the rationale for grouping experts in a department was not the academic 
discipline but the generic property of the product the researchers were working on: e.g. 
biodegradability, fluorescence, anti-foam. Within these departments, “technological 
projects” were also set up and specifically dedicated to developing new expertise. 
Technological projects were especially important in the run strategy, where the timing 
of development sometimes hindered the exploration of new technical options that might 
take too long to master.  
The main differences between these two innovative strategies, as far as internal 
organization is concerned, appeared to be the following. 
First, in the run strategy the customer was strongly associated with and almost a part of, 
the project team. In contrast, in the block strategy, a rather strict border existed between 
the development team and the customer. 
The second main difference is related to the actor with which development partnerships 
were set up. In the run strategy, partnerships involved the customers themselves, will 
thus be called downstream partnerships. In the block strategy on the other hand, 
partnerships involved research centers and academic units to be called further upstream 
partnerships. 
In light of this case and the issues that have been raised thus far, the concern  for 
implementing a dual strategy—combining blocking and running—would be to 
simultaneously stipulate an upstream focus for the block strategy and a downstream one  
for the run strategy. On one hand, long-term projects, typical of the block strategy, 
elaborating on the company’s expertise and its upstream partnerships have to be set up. 
On the other, short-term projects involving customers in learn and probe processes and 
expanding down stream relationships are also to be structured. One issue is to 
differenciate these two kinds of projects. But establishing and maintaining relationships 
between experts involved in the two kinds of projects is also crucial for maintaining the 
efficiency of the design department. In order to deal with this dual strategy, this 
organization should evolve toward a specialization of experts in one or the other type of 
project. At the same time, the departments should group the experts according to their 
expertise whatever kind of project they are involved with.  
Of course, there are limitations to our study. Our focus on one case and one industry 
raises the question of the generalizability of our conclusions. On the basis of this long-
term and in-depth study some issues were raised that can be investigated on a larger 
scale: the role of downstream development partnerships in the run strategy in various 
industries ; a comparison of how departments are structured within the research 
function of firms in the same industry and how this “organizational design parameter 
relates to the development of specific expertises. 
 Another path worth to following would be to analyze the case of a company that has 
adopted a combined strategy. The semi-conductor industry is the first one think of, the 
cosmetics or the food industry are far less studied but could be a sector with some firms 
having such a dual strategy.     
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